SCHEMBL13698782

SCHEMBL13698782

COC(=O)c1cc(C)c(F)cc1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.47
MAPT P10636 5/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.44
APEX1 P27695 1/20 0.44
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
ABL1 P00519 1/20 0.41
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HTT P42858 2/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
NPSR1 Q6W5P4 2/20 0.39
PTGS2 P35354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL448027 0.93 GAA (0.47) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL1110997 0.87 GAA (0.57) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL4508725 0.86 HPGD (0.46) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL3436881 0.85 MAPT (0.42) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL14590043 0.85 GAA (0.47) GAAMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL31024710 0.85 MAPT (0.42) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL20470613 0.83 PDGFRB (0.42) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL14186809 0.83 MAPT (0.41) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL29046663 0.82 MAPT (0.48) GAAMAPTLMNAHPGDSMN1; SMN2
SCHEMBL9248547 0.81 ALPL (0.50) GAAMAPTLMNAHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS MEINGASSNER JOSEF GOTTFRIED 2009-09-10 US disclosed
US-7482462-B2 Acylsulfonamides as inhibitors of steroid sulfatase NOVARTIS AG (CH) 2009-01-27 US disclosed
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin NOVARTIS AG (CH) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293758-A1 Combination of a Steroid Sulfatase Inhibitor and an Ascomycin STS, ARSA, CYP17A1 GAA 204/4885MAPT 3209/4885LMNA 4393/4885
US-20090227620-A1 ANTI-INFLAMMATORY COMPOUNDS STS, SERPINB1, MPO GAA 217/4885MAPT 3544/4885LMNA 4383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.